CYCN Key Statistics, Chart & Performance
The current stock price of CYCN is 1.45 USD. In the past month the price increased by 20.83%. In the past year, price decreased by -63.01%.
CYCN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CYCN. When comparing the yearly performance of all stocks, CYCN is a bad performer in the overall market: 93.32% of all stocks are doing better.
CYCN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYCN. CYCN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CYCN Financial Highlights
Over the last trailing twelve months CYCN reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS increased by 46.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.11% | ||
| ROE | -23.06% | ||
| Debt/Equity | 0 |
CYCN Forecast & Estimates
CYCN Ownership
About CYCN
Company Profile
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The firm is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. The company is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The firm has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Company Info
CYCLERION THERAPEUTICS INC
301 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Peter M. Hecht
Employees: 1
Phone: 16176217722
CYCLERION THERAPEUTICS INC / CYCN FAQ
What does CYCLERION THERAPEUTICS INC do?
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The firm is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. The company is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The firm has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Can you provide the latest stock price for CYCLERION THERAPEUTICS INC?
The current stock price of CYCN is 1.45 USD. The price decreased by -3.33% in the last trading session.
Does CYCLERION THERAPEUTICS INC pay dividends?
CYCN does not pay a dividend.
How is the ChartMill rating for CYCLERION THERAPEUTICS INC?
CYCN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is CYCN stock listed?
CYCN stock is listed on the Nasdaq exchange.
What is the ownership structure of CYCLERION THERAPEUTICS INC (CYCN)?
You can find the ownership structure of CYCLERION THERAPEUTICS INC (CYCN) on the Ownership tab.
What is the outstanding short interest for CYCLERION THERAPEUTICS INC?
The outstanding short interest for CYCLERION THERAPEUTICS INC (CYCN) is 4.02% of its float.